The company’s technology is focused on development of agonist to target the melanocortin system . The melanocortin system is activated in inflammatory conditions and contributes with anti- inflammatory effects, and stimulates important components of the healing process and for recovery to normal tissue function. SynAct’s drug candidate AP1189 is first in class compound reaching the melanocortin system for once daily oral ...
The company’s technology is focused on development of agonist to target the melanocortin system . The melanocortin system is activated in inflammatory conditions and contributes with anti- inflammatory effects, and stimulates important components of the healing process and for recovery to normal tissue function. SynAct’s drug candidate AP1189 is first in class compound reaching the melanocortin system for once daily oral dosing that stimulates the relevant receptors in the melanocortin system, and thereby avoiding unwanted side effects.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.